Things could hardly have gone worse for healthcare investors in 2023. While shares of Eli Lilly and Novo Nordisk rocketed amid excitement about their new.
Piper Sandler analysts boost their year-end price target for the S&P 500 to 4,825 from 4,625, implying a roughly 5.2% upside from the large-cap index’s.